GSK GSK plc

Markets are back to obsessing over central bank signals, supply routes and growth downgrades, and that mix is shaking up how investors look at reliable income. When credit feels tighter and headlines keep flagging disruption risks, steady dividend cheques from global healthcare stocks can suddenly look more interesting. This piece walks through three healthcare dividend payers from our screener that appear closely exposed to the latest macro news and explains why their stories might matter to...

Fresh funding from the Gates Foundation for AN2 Therapeutics’ tuberculosis collaboration with GSK (LSE:GSK) has put the pharma group’s boron based LeuRS inhibitor program back in focus for investors. The GSK share price has softened in the very short term, with a 1-day share price return of a 0.22% decline and a 7-day share price return of a 2.62% decline, even as fresh R&D headlines such as the Gates backed TB work and recent conference appearances keep the pipeline in view. Yet momentum...

GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.

Investment bank Jefferies has kept its ‘buy’ rating and 2,500p target on GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 drugmaker, after a fireside chat with its chief scientific officer reinforced its view that B7H3 is one of GSK's most underappreciated opportunities. The target implies 35%...

MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.

GSK plc (NYSE:GSK) has spent much of 2026 adding new drugs to its pipeline, and Berenberg is starting to think investors aren’t giving it enough credit. Berenberg analyst Kerry Holford upgraded GSK from Hold to Buy and raised the firm’s price target to 2,200p from 2,000p on September 15. Berenberg said it is “increasingly optimistic” […]

GSK plc (NYSE:GSK) is adding another cancer drug to a pipeline that has been getting considerably more attention under CEO Luke Miels. The company has agreed to acquire full global rights to a trispecific T-cell engager from China-based Chimagen Biosciences in a deal worth up to $750 million. GSK (NYSE:GSK) plans to develop the experimental […]

On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. Under the agreement, HUTCHMED receives a $110 million upfront payment, potential milestone payments up to $1.3 billion, and tiered royalties on net sales, while granting GSK worldwide rights […]

GSK (NYSE:GSK) is advancing a respiratory and immunology pipeline centered on longer-acting biologics, more targeted patient selection and combination approaches, according to Kaivan Khavandi, the company’s senior vice president and global head of Translational and Development Sciences. Speaking at

GSK (NYSE:GSK) Chief Financial Officer Julie Brown outlined the company’s growth strategy, launch priorities and cost-savings plans during a discussion with Bank of America analyst Sachin Jain following the company’s recent capital markets day. Brown said GSK’s strategic portfolio review identified

European equities traded in the US as American depositary receipts started the week higher on Monday

European equities traded in the US as American depositary receipts were heading lower late Friday mo

GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a simple question for investors who care about valuation. Is the current price you see on screen today adequately supported by the earnings power of the business? Over the past 5 years GSK shares have returned 58.4%, which puts real weight on whether the current earnings justify where the stock now trades. Recent deals in cancer therapies, including new T cell engager and...

GSK (LSE:GSK) agreed to acquire Chimagen's trispecific T cell-engager candidate for multiple myeloma, expanding its blood cancer research portfolio. The drug asset is described by the parties as a potential best in class trispecific T cell therapy targeting multiple myeloma. GSK plans to close its German vaccine manufacturing site and consolidate production in Canada, with associated job reductions and supply chain changes. The acquisition of Chimagen's trispecific T cell-engager and the...

A growing body of research suggests Shingrix can reduce the risk of heart disease and delay dementia.

GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of internal research and business development, according to Hesham Abdullah, the company’s senior vice pre

Healthcare stocks were edging lower late Tuesday afternoon, with the NYSE Healthcare Index and the S

Healthcare stocks were edging down Tuesday afternoon, with the NYSE Healthcare Index fractionally lo

GSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.

GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The decision reflects declining demand for traditional egg-based flu vaccines, which has left GSK with more manufacturing capacity than it needs. GSK reviewed its Dresden and Ste-Foy, Canada, flu vaccine sites and chose to […]

GSK (GSK) agreed to acquire global rights to an experimental T-cell engager therapy for multiple mye

GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay up to $750 million for an experimental cancer therapy from the privately owned Chinese biotech Chimagen Biosciences. The pharmaceuticals group will hand over an undisclosed upfront fee to secure full global rights to the programme. Chimagen...

Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.

Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index up 1.6% and the State St

GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.

European equities traded in the US as American depositary receipts opened the week tracking sharply

Shares rose after strong clinical data strengthened the case for its $10.6 billion Nuvalent acquisition and broader push to rebuild oncology around lung cancer.

Healthcare stocks were rising premarket Monday, with the State Street Health Care Select Sector SPDR

Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.

GSK (NYSE:GSK) is accelerating investment in research and development, expanding its late-stage pipeline and targeting cost savings to support product launches while maintaining profitability through upcoming HIV patent expirations, Chief Financial Officer Julie Brown said during a company discussio

GSK plc (NYSE:GSK) is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid-stage results in both younger and older adults. The mRNA-based candidate generated stronger immune responses than currently approved standard- and high-dose flu vaccines, according to GSK (NYSE:GSK). Its design also targets two important surface proteins on the influenza virus rather […]

GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.

Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and th

The shingles vaccine costs nothing under Medicare Part D, yet thousands of beneficiaries walk out of their doctor's office owing hundreds of dollars for the exact same shot. The billing system has a gap, and most patients have no idea it exists until they're already holding the receipt.

GSK plc (NYSE:GSK) has reached two important regulatory milestones involving treatments for chronic hepatitis B and rectal cancer. Bepirovirsen, which is now branded as Hibsago, was approved by Japan, marking the drug’s first authorization anywhere in the world. In a separate development, the FDA granted priority review to an application seeking approval of GSK’s (NYSE:GSK) […]

GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last...

Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.

MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to...

GSK to advance its mRNA flu vaccine into phase III after phase II study has shown stronger immune responses and good tolerability.

GSK stock has delivered a strong 54.4% total return over the past five years, yet current valuation checks still suggest the shares lean cheap rather than fully priced in. That mix of solid long term gains and a high value score raises the question of whether the market is still underestimating the company. Over the past 5 years, GSK has returned 54.4%, which points to meaningful value creation for longer term holders despite some recent short term share price softness. The planned Phase 3...

GSK (LSE:GSK) has received the world's first regulatory approval for Hibsago (bepirovirsen) as a functional cure for chronic hepatitis B virus infection in Japan. The Japanese approval follows Phase III trial data that showed significant functional cure rates in patients with chronic hepatitis B. The decision represents an important development for GSK's pipeline and may influence the standard of care for chronic hepatitis B treatment globally. For readers tracking how advances like GSK's...

GSK (LSE:GSK) is back in focus after presenting positive phase II data for its mRNA seasonal flu vaccine and confirming plans to start a phase III trial in September 2026, following Fast Track designation in the US. Against this backdrop of pipeline news, GSK’s share price has shown mixed short term momentum, with a 1-day share price return of 0.97% but a 30-day share price return that is down 3.11%, while the 1-year total shareholder return of 34.36% points to much stronger longer term...

GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.

GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real value of mRNA technology sits right now.

GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.

GSK plc (NYSE:GSK) plans to launch a Phase 3 clinical trial in September for its experimental mRNA seasonal influenza vaccine after achieving superior immune responses in mid-stage testing compared to currently licensed vaccines. Strong Mid-Stage Results Data presented at the OPTIONS XIII Conference for the Control of Influenza revealed that the company’s vaccine candidate generated higher immune responses against every tested strain than standard and high-dose inactivated vaccines in both young

European equities traded in the US as American depositary receipts were trending lower late Thursday

GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively tr